Inflammatory process in Parkinson disease: neuroprotection by neuropeptide Y.
Animals
Corpus Striatum
/ drug effects
Disease Models, Animal
Dopamine
/ metabolism
Dopamine Plasma Membrane Transport Proteins
/ metabolism
Dopaminergic Neurons
/ drug effects
Inflammation
/ drug therapy
Male
Microglia
/ drug effects
Nerve Degeneration
/ drug therapy
Neuropeptide Y
/ pharmacology
Neuroprotection
/ drug effects
Oxidopamine
/ pharmacology
Parkinson Disease
/ drug therapy
Rats
Rats, Wistar
Substantia Nigra
/ drug effects
Parkinson disease
inflammation
neuropeptide Y
neuroprotection
Journal
Fundamental & clinical pharmacology
ISSN: 1472-8206
Titre abrégé: Fundam Clin Pharmacol
Pays: England
ID NLM: 8710411
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
28
11
2018
revised:
26
02
2019
accepted:
08
03
2019
pubmed:
14
3
2019
medline:
9
4
2020
entrez:
14
3
2019
Statut:
ppublish
Résumé
Parkinson's disease (PD) is characterized by the degeneration of dopaminergic neurons in the nigro-striatal pathway. Interestingly, it has already been shown that an intracerebral administration of neuropeptide Y (NPY) decreases the neurodegeneration induced by 6-hydroxydopamine (6-OHDA) in rodents and prevents loss of dopamine (DA) and DA transporter density. The etiology of idiopathic PD now suggest that chronic production of inflammatory mediators by activated microglial cells mediates the majority of DA-neuronal tissue destruction. In an animal experimental model of PD, the present study shows that NPY inhibited the activation of microglia evaluated by the binding of the translocator protein (TSPO) ligand [3H]PK11195 in striatum and substantia nigra of 6-OHDA rats. These results suggest a potential role for inflammation in the pathophysiology of the disease and a potential treatment by NPY in PD.
Substances chimiques
Dopamine Plasma Membrane Transport Proteins
0
Neuropeptide Y
0
Oxidopamine
8HW4YBZ748
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
544-548Informations de copyright
© 2019 Société Française de Pharmacologie et de Thérapeutique.
Références
Jellinger K.A. The pathology of Parkinson's disease. Adv. Neurol. (2001) 86 55-72.
Bartels A.L., Leenders K.L. Neuroinflammation in the pathophysiology of Parkinson's disease: evidence from animal models to human in vivo studies with [11C]-PK11195 PET. Mov. Disord. (2007) 22 1852-1856.
Koshimori Y., Ko J.H., Mizrahi R. et al. Imaging striatal microglial activation in patients with Parkinson's disease. PLoS ONE (2015) 10 e0138721.
Liu B., Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. (2003) 304 1-7.
Papadopoulos V., Baraldi M., Guilarte T.R. et al. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol. Sci. (2006) 27 402-409.
Sutter A.P., Maaser K., Höpfner M. et al. Specific ligands of the peripheral benzodiazepine receptor induce apoptosis and cell cycle arrest in human esophageal cancer cells. Int. J. Cancer (2002) 102 318-327.
Benavides J., Quarteronet D., Imbault F. et al. Labelling of “peripheral-type” benzodiazepine binding sites in the rat brain by using [3H]PK 11195, an isoquinoline carboxamide derivative: kinetic studies and autoradiographic localization. J. Neurochem. (1983) 41 1744-1750.
Benavides J., Fage D., Carter C., Scatton B. Peripheral type benzodiazepine binding sites are a sensitive indirect index of neuronal damage. Brain Res. (1987) 421 167-172.
Messmer K., Reynolds G.P. Increased peripheral benzodiazepine binding sites in the brain of patients with Huntington's disease. Neurosci. Lett. (1998) 241 53-56.
Turkheimer F.E., Rizzo G., Bloomfield P.S. et al. The methodology of TSPO imaging with positron emission tomography. Biochem. Soc. Trans. (2015) 43 586-592.
Adrian T.E., Allen J.M., Bloom S.R. et al. Neuropeptide Y distribution in human brain. Nature (1983) 306 584-586.
Allen Y.S., Adrian T.E., Allen J.M. et al. Neuropeptide Y distribution in the rat brain. Science (1983) 221 877-879.
Wettstein J.G., Earley B., Junien J.L. Central nervous system pharmacology of neuropeptide Y. Pharmacol. Ther. (1995) 65 397-414.
Alvaro A.R., Martins J., Costa A.C. et al. Neuropeptide Y protects retinal neural cells against cell death induced by ecstasy. Neuroscience (2008) 152 97-105.
Silva A.P., Pinheiro P.S., Carvalho A.P. et al. Activation of neuropeptide Y receptors is neuroprotective against excitotoxicity in organotypic hippocampal slice cultures. FASEB J. (2003b) 17 1118-1120.
Thiriet N., Deng X., Solinas M. et al. Neuropeptide Y protects against methamphetamine-induced neuronal apoptosis in the mouse striatum. J. Neurosci. (2005) 25 5273-5279.
Duarte-Neves J., Pereira de Almeida L., Cavadas C. Neuropeptide Y (NPY) as a therapeutic target for neurodegenerative diseases. Neurobiol. Dis. (2016) 95 210-224.
Kerkerian L., Bosler O., Pelletier G., Nieoullon A. Striatal neuropeptide Y neurones are under the influence of the nigrostriatal dopaminergic pathway: immunohistochemical evidence. Neurosci. Lett. (1986) 66 106-112.
Kerkerian L., Salin P., Nieoullon A. Pharmacological characterization of dopaminergic influence on expression of neuropeptide Y immunoreactivity by rat striatal neurons. Neuroscience (1988) 26 809-817.
Cannizzaro C., Tel B.C., Rose S., Zeng B.Y., Jenner P. Increased neuropeptide Y mRNA expression in striatum in Parkinson's disease. Brain Res. Mol. Brain Res. (2003) 110 169-176.
Decressac M., Pain S., Chabeauti P.Y. et al. Neuroprotection by neuropeptide Y in cell and animal models of Parkinson's disease. Neurobiol. Aging (2012) 33 2125-2137.
Ferreira R., Xapelli S., Santos T. et al. Neuropeptide Y modulation of interleukin-1{beta} (IL-1{beta})-induced nitric oxide production in microglia. J. Biol. Chem. (2010) 285 41921-41934.
Ferreira R., Santos T., Cortes L. et al. Neuropeptide Y inhibits interleukin-1 beta-induced microglia motility. J. Neurochem. (2012) 120 93-105.
Paxinos G., Watson C. The rat brain in stereotaxic coordinates, 6th edn. Academic Press, San Diego, CA, 2007.
Maia S., Arlicot N., Vierron E. et al. Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6-hydroxydopamine rat model of Parkinson's disease. Synapse (2012) 66 573-583.
Fellner L., Jellinger K.A., Wenning G.K., Stefanova N. Glial dysfunction in the pathogenesis of α-synucleinopathies: emerging concepts. Acta Neuropathol. (2011) 121 675-693.
Prafulla Chandra T., Rishi P. The potential role of neuroinflammation and transcription factors in Parkinson disease. Dialogues Clin. Neurosci. (2017) 19 71-80.
Tansey M.G., Goldberg M.S. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol. Dis. (2010) 37 510-518.
Ouchi Y., Yagi S., Yokokura M., Sakamoto M. Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat. Disord. (2009) 15(Suppl 3) S200-S204.
Akiyama H., McGeer P.L. Microglial response to 6-hydroxydopamine-induced substantia nigra lesions. Brain Res. (1989) 489 247-253.
Depino A.M., Earl C., Kaczmarczyk E. et al. Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur. J. Neurosci. (2003) 18 2731-2742.
Rodrigues R.W., Gomide V.C., Chadi G. Astroglial and microglial reaction after a partial nigrostriatal degeneration induced by the striatal injection of different doses of 6-hydroxydopamine. Int. J. Neurosci. (2001) 109 91-126.
Rodrigues R.W., Gomide V.C., Chadi G. Astroglial and microglial activation in the wistar rat ventral tegmental area after a single striatal injection of 6-hydroxydopamine. Int. J. Neurosci. (2004) 114 197-216.
Gomide V.C., Silveira G.A., Chadi G. Transient and widespread astroglial activation in the brain after a striatal 6-OHDA-induced partial lesion of the nigrostriatal system. Int. J. Neurosci. (2005) 115 99-117.
Malva J.O., Xapelli S., Baptista S. et al. Multifaces of neuropeptide Y in the brain-neuroprotection, neurogenesis and neuroinflammation. Neuropeptides (2012) 46 299-308.
Obuchowicz E., Antkiewicz-Michaluk L., Romanska I., Herman Z.S. Increased striatal neuropeptide Y immunoreactivity and its modulation by deprenyl, clonidine and L-dopa in MPTP-treated mice. J. Neural. Transm. (2003) 110 1375-1391.